HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, M. Articles by Goldfine, I. D. Search for Related Content PubMed PubMed Citation Articles by Li, M. Articles by Goldfine, I. D. Social Bookmarking                What's this?

Small Molecule Insulin Receptor Activators Potentiate Insulin Action in Insulin-Resistant Cells

¹ University of California at San Francisco, Mount Zion Medical Center, San Francisco, California
² Telik, San Francisco, California
³ Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey

In type 2 diabetes, impaired insulin signaling leads to hyperglycemia and other metabolic abnormalities. To study a new class of antidiabetic agents, we compared two small, nonpeptide molecules that activate insulin receptor (IR) ß-subunit tyrosine kinase activity: Merck L7, a direct IR agonist, and Telik’s TLK16998, an IR sensitizer. In rat hepatoma cells (HTCs) that overexpress the IR (HTC-IR), IR autophosphorylation was directly activated by L7 in the absence of insulin. TLK16998 did not directly activate IR autophosphorylation, but it enhanced IR autophosphorylation in the presence of insulin. Tyrosine phosphorylation of an endogenous 185-kDa IR substrate was also significantly enhanced by both Merck L7 alone and TLK16998 plus insulin. Adding TLK16998 to L7 produced synergistic effects, further indicating that these two compounds act on the IR through separate mechanisms. We next studied HTC-IR_485–599 cells, which overexpress a mutant IR with a deletion in the -subunit connecting domain that does not undergo autophosphorylation in response to insulin binding. L7 was able to directly activate autophosphorylation of the deletion mutant IR in these cells, whereas TLK16998 had no effect. Compounds were then tested in three other cell models of impaired IR function. Both TLK16998 and Merck L7 improved IR autophosphorylation in cells with diminished IR signaling due to either treatment with tumor necrosis factor- or overexpression of membrane glycoprotein PC-1. However, in TPA (tetradecanoylphorbol acetate)-treated cells, TLK16998 but not Merck L7 was able to significantly reverse the impaired insulin-stimulated IR autophosphorylation. In summary, these two classes of IR activators selectively increased IR function in a variety of insulin-resistant cell lines.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. A. Velliquette, J. E. Friedman, J. Shao, B. B. Zhang, and P. Ernsberger Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor {gamma} Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 422 - 430. [Abstract] [Full Text] [PDF]

				H. Dong, B. A. Maddux, J. Altomonte, M. Meseck, D. Accili, R. Terkeltaub, K. Johnson, J. F. Youngren, and I. D. Goldfine Increased Hepatic Levels of the Insulin Receptor Inhibitor, PC-1/NPP1, Induce Insulin Resistance and Glucose Intolerance Diabetes, February 1, 2005; 54(2): 367 - 372. [Abstract] [Full Text] [PDF]

				S. Li, N. D. Covino, E. G. Stein, J. H. Till, and S. R. Hubbard Structural and Biochemical Evidence for an Autoinhibitory Role for Tyrosine 984 in the Juxtamembrane Region of the Insulin Receptor J. Biol. Chem., July 3, 2003; 278(28): 26007 - 26014. [Abstract] [Full Text] [PDF]

				C. Pender, I. D. Goldfine, V. P. Manchem, J. L. Evans, W. R. Spevak, S. Shi, S. Rao, S. Bajjalieh, B. A. Maddux, and J. F. Youngren Regulation of Insulin Receptor Function by a Small Molecule Insulin Receptor Activator J. Biol. Chem., November 8, 2002; 277(46): 43565 - 43571. [Abstract] [Full Text] [PDF]

				M. Li, J. F. Youngren, A. Dunaif, I. D. Goldfine, B. A. Maddux, B. B. Zhang, and J. L. Evans Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4088 - 4093. [Abstract] [Full Text] [PDF]